3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Unknown
1
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Other hematologic neoplasm
2
Gastrointestinal
2
CNS
2
Tumor-Agnostic
1
Myeloid
1
Gynecologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Imatinib Mesylate
17
Cytarabine
13
Azacitidine
13
Cyclophosphamide
11
Decitabine
9
Dasatinib
9
Etoposide
8
nilotinib
7
Peripheral Blood Stem Cell Transplantation
7
Busulfan
7
Tacrolimus
6
Polymerase Chain Reaction
6
Idarubicin
6
Antilymphocyte Serum
6
fludarabine phosphate
5
Mycophenolic Acid
5
Melphalan
5
Blood Specimen Collection
5
ruxolitinib
4
pegaspargase
4
fludarabine
4
Whole-Body Irradiation
4
Radiotherapy
4
Methylprednisolone
4
Hydroxyurea
4
Filgrastim
4
ponatinib
3
Surveys and Questionnaires
3
Rituximab
3
Lenalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Tyrosine Kinase Inhibitors
×
Myeloid
×
Clear all
NCT02687425
2016-02-22
SESPI
Tongji Hospital
Phase 2
Unknown
20 enrolled